some searches from pubmed:
pic from PMC7102549
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102587/
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
Italian Society of Infectious and Tropical Diseases (Lombardy Section)
http://www.simit.org/medias/1555-covid19-linee-guida-trattamento-01mar.pdf Last accessed on 20th March 2020.
Mild to moderate COVID-19:
Lopinavir/ritonavir plus Chloroquine 500 mg × 2/day or Hydroxychloroquine 200 mg per day for 10 days.
Severe or critical COVID-19:
Remdesivir plus Chloroquine 500 mg × 2/day or Hydroxychloroquine 200 mg per day for 10–20 days.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054408/
Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020
https://www.ncbi.nlm.nih.gov/pubmed/32297571
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial